SR-31747
目录号 : GC31805SR-31747 是一种具有免疫抑制和抗炎特性的 sigma 配体。
Cas No.:132173-06-9
Sample solution is provided at 25 µL, 10mM.
SR-31747 is a new sigma ligand with immunosuppressive properties.
SR-31747 is capable of inhibiting T-cell proliferation when added as late as 24 h after activation. SR-31747 arrests proliferation in yeast cells in a dose-dependent manner[2].
SR 31747 dramatically blocks lipopolysaccharide-induced production of interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha in a dose-dependent manner (ED50 2 mg/kg)[1].
[1]. Derocq JM, et al. In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747. J Pharmacol Exp Ther. 1995 Jan;272(1):224-30. [2]. Silve S, et al. The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol Cell Biol. 1996 Jun;16(6):2719-27.
Animal experiment: |
IL-1, IL-6 and TNF-a are induced by i.p. injection of LPS into BALBIc mice. SR 31747 or reference substances are administered i.p. at the indicated doses together with LPS (0.5 mg/kg). Control animals are treated with LPS and vehicle. Blood samples are collected from the retro-orbital sinus 1 hr or 4 hr after LPS injection for the determination of TNF-α, IL-1 and IL-6. Plasma is prepared and stored frozen until experiments. The IL-1 plasma level is determined by a competitive radioreceptor assay with the use of the murine NOBEL4 cell line and [125I]-IL-1. The IL-6 assay is conducted with the B9 murine IL-6-dependent cell line. The TNF-a plasma level is evaluated by the cytolytic assay with the dactinomycin-treated LM6 cell line, derived from the murine fibroblastic L929 cell line. Each determination is performed on a pool of three different plasma samples. None of the molecules administered affect these assays even at the highest dose (10-5 M), which thereby rules out the possibility of any direct effect caused by the presence ofdrugs in treated-animal sera. In the various tests, one unit is defined as the amount of cytokines able to induce 50% of the maximal effect. |
References: [1]. Derocq JM, et al. In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747. J Pharmacol Exp Ther. 1995 Jan;272(1):224-30. |
Cas No. | 132173-06-9 | SDF | |
Canonical SMILES | CCN(C/C=C\C1=CC=C(C2CCCCC2)C(Cl)=C1)C3CCCCC3 | ||
分子式 | C23H34ClN | 分子量 | 359.98 |
溶解度 | DMSO : 5 mg/mL (13.89 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.7779 mL | 13.8897 mL | 27.7793 mL |
5 mM | 0.5556 mL | 2.7779 mL | 5.5559 mL |
10 mM | 0.2778 mL | 1.389 mL | 2.7779 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet